Cardiovascular Diabetology

Table 4 The summary of subgroup analyses

From: Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis

Subgroup analysis	Subjects
Subgroup analysis	SGLT-2 inhibitors	GLP-1 RAs	Comparison	Risk ratio	95% CI	I² (%)	p value
MACE-3
eGFR 30-44	2479	1934	SGLT-2 inhibitors vs. placebo	0.73	0.54–0.97	57.1	0.063
			GLP-1 RAs vs. placebo	1.02	0.78–1.33
			SGLT-2 inhibitors vs. GLP-1 RAs	0.72	0.48–1.06
eGFR 45-59	3974	4576	SGLT-2 inhibitors vs. placebo	0.82	0.66–1.01	44.8	0.12
			GLP-1 RAs vs. placebo	0.85	0.71–1.03
			SGLT-2 inhibitors vs. GLP-1 RAs	0.96	0.72–1.27
Renal outcomes
eGFR 30-44	2420	889	SGLT-2 inhibitors vs. placebo	0.75	0.62–0.91	0	0.69
			GLP-1 RAs vs. placebo	0.78	0.46–1.32
			SGLT-2 inhibitors vs. GLP-1 RAs	0.96	0.55–1.29
eGFR 45-59	3976	2288	SGLT-2 inhibitors vs. placebo	0.61	0.48–0.77	0	0.52
			GLP-1 RAs vs. placebo	1.18	0.76–1.84
			SGLT-2 inhibitors vs. GLP-1 RAs	0.52	0.31–0.85

SGLT2i sodium-glucose cotransporter-2 inhibitors, GLP-1 RAs glucagon-like peptide-1 receptor agonists, eGFR estimated glomerular filtration rate, CI confidence intervals, MACE-3 3-point major adverse cardiovascular event, vs. versus, N/A not available

Back to article page

ISSN: 1475-2840

Contact us

Submission enquiries: journalsubmissions@springernature.com